Breaking the mold with #RNA—a# “ #RNAissance# ” of life science. . #RNAtherapeutics# #RNAdrugs# #Oligonucleotides# #mRNAtherapeutics# #mRNA# #siRNA# #RNAi# #Antisenseoligonucleotides# #Antisenseoligonucleotides# #ASO# #NucleicAcids# .

ADARX PHARMACEUTICALS TARGETS $1.74B VALUATION IN U.S. IPO RNA drug developer ADARx Pharmaceuticals plans to sell 21.875M shares at $15-$17 each, raising up to $371.9M and valuing the company at as much as $1.74B. AbbVie will separately purchase about 5.01M shares in a concurrent private placement, giving it roughly a 4.9% stake after the IPO. ADARx is developing next-generation siRNA drugs, with five wholly owned programs spanning hereditary angioedema, complement diseases, stroke prevention, obesity and neurodegenerative diseases. Its most advanced drug, onvuzosiran, is currently in Phase 3 for hereditary angioedema, with topline data expected by the end of 2027. The FDA granted the program Fast Track status in August. At the $16 midpoint, ADARx expects roughly $397M in combined net proceeds from the IPO and AbbVie placement, with the largest allocations planned for: • $180M for agazisiran and its complement-disease programs • $80M for stroke candidate ADX-626 • $65M for Phase 3 onvuzosiran • $25M for obesity program ADX-077 • $20M for neurodegeneration program ADX-199 The company says the proceeds, together with existing cash and investments, should fund operations into 2030. ADARx plans to list on Nasdaq under $ADRX. Source: SEC filing, Reuters

🧬 One of the benefits of RNA therapies: by injecting code instead of peptides, the body does the manufacturing internally, over long periods of time. Today’s news: Moonwalk’s oversubscribed $70M Series B with Eli Lilly to fund first-in-human studies. PharmaExec: “Across multiple preclinical studies, Moonwalk demonstrated reductions in both body weight and fat mass while still preserving lean muscle mass, and without reducing food intake.” “Moonwalk's programs are designed to selectively deliver siRNA therapeutics directly to adipose tissue, enabling precise modulation of novel, non-incretin pathways underlying obesity. The company combines AI reasoning with human genetics, epigenomics and multi-omics discovery and proprietary tissue-targeting chemistry to unlock previously inaccessible biology, with the goal of developing first-in-class medicines.” "Obesity is one of the most significant global health challenges, and Moonwalk is pursuing a fundamentally different approach to treating it," said Rick Gerson, CEO of Alpha Wave Global. "By targeting adipose tissue directly, Moonwalk may redefine how obesity is treated by delivering therapies with the potential for durable efficacy, lean muscle preservation and infrequent dosing."” — from • Deeper dive: • Company:

Sironax is about halfway to its enrollment target in a Phase 2 trial of an oral NAMPT activator for adults with obesity. #longevity# #geroscience# #Sironax# #NAMPT# #obesity#

SIGNAL IDUNA empowered 10K+ employees to build custom agents in just six months with Gemini Enterprise—delivering 80% weekly adoption, 200+ agents built in two weeks, and a 400% boost in its internal knowledge agent, the Co SI Health Assistant ↓

Signal Strength Stocks 📈 These are the names our community has been riding. Signal Strength Stocks uses Hedgeye CEO @KeithMcCullough’s proprietary signaling model to identify stocks with Bullish TRADE and TREND signals. Get access to the full list, updated daily:

Signal, iMessage and Cloudflare have already upgraded to quantum resistant encryption. Quantus CEO Christopher Smith explains why Bitcoin will have a much harder time. "With Bitcoin, not only do you have to implement the technology, which Bitcoin is notoriously slow at doing," "You also have to migrate people to the new technology." "Signal private messenger, iMessage, Cloudflare. They already went post-quantum." "And just nobody noticed." @YuviLightman @QuantusNetwork